Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

CEO Stéphane Bancel said the vaccine maker aims to reduce 2025 cash costs by $1 billion with a plan for an additional $500 million in 2026. It expects to end 2025 with cash and investments of about $6 ...

Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.

CEO Larry Ellison’s claims that artificial intelligence (AI) could help develop messenger RNA-based (mRNA) vaccines to cure ...

It was a Chinese media outlet that reported that Chief Executive Stéphane Bancel was visiting Shanghai to sign a pact with local authorities for Moderna to research, develop and manufacture ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

CEO Stéphane Bancel emphasised saving cash as integral in the company’s bid to parlay Covid-19 profits into future profitability.

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Only 23 countries use climate data for health surveillance, says head of WMO, adding more collaboration needed ...